Taltz (ixekizumab) for the Treatment of Non-Radiographic Axial Spondyloarthritis

Source :: Legal Monitor Worldwide. June 12, 2020
Publication Year :: 2020
Abstract: Taltz (ixekizumab) is the first humanised interleukin (IL)-17A antagonist therapy approved for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA) in adult patients with objective inflammation signs. The therapy is [...]

Subjects :: United States. Food and Drug Administration
Ixekizumab
Drug approval
Business, international
Law
Taltz (Medication)

Tools